Rheumatoid Arthritis (RA) Pipeline Landscape Market Report 2021: Comprehensive Insights About 100+ Companies & Respective Pipeline Drugs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Rheumatoid Arthritis (RA) - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This Rheumatoid Arthritis (RA) - Pipeline Insight, 2021 provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Rheumatoid Arthritis (RA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Rheumatoid Arthritis (RA) R&D. The therapies under development are focused on novel approaches to treat/improve Rheumatoid Arthritis (RA).

Rheumatoid Arthritis (RA) Emerging Drugs Chapters

This segment of the Rheumatoid Arthritis (RA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rheumatoid Arthritis (RA) Emerging Drugs

Ozoralizumab: Taisho Pharmaceutical

Ozoralizumab (ATN-103) is a trivalent humanized low molecular weight compound that combines two anti-TNF? NANOBODY VHHs and one anti-serum albumin NANOBODY VHH. Ozoralizumab is about a quarter of the size of conventional IgG antibodies. Ozoralizumab binds to two subunits of TNF and potently neutralizes its action. Ozoralizumab, initially discovered by Ablynx.

In March 2021, Taisho announced that it submitted an application for approval to manufacture and market the anti-TNF? NANOBODY therapeutic (generic name: ozoralizumab) to the Ministry of Health, Labour and Welfare for rheumatoid arthritis (RA).

ABX464: Abivax

ABX464 is an oral, first-in-class, small molecule that binds to the RNA cap binding protein (CBC 80/20) complex which sits at the 5' end of every RNA molecule and enhances pre-mRNA splicing. The drug is in Phase II clinical studies for the treatment of Rheumatoid Arthritis (RA).

Rheumatoid Arthritis (RA): Therapeutic Assessment

This segment of the report provides insights about the different Rheumatoid Arthritis (RA) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Rheumatoid Arthritis (RA)

There are approx. 100+ key companies which are developing the therapies for Rheumatoid Arthritis (RA). The companies which have their Rheumatoid Arthritis (RA) drug candidates in the most advanced stage, i.e. Preregistration include, Taisho Pharmaceutical.

Phases

This report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Rheumatoid Arthritis (RA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rheumatoid Arthritis (RA): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Rheumatoid Arthritis (RA) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rheumatoid Arthritis (RA) drugs.

Rheumatoid Arthritis (RA) Report Insights

• Rheumatoid Arthritis (RA) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Rheumatoid Arthritis (RA) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Rheumatoid Arthritis (RA) drugs?
• How many Rheumatoid Arthritis (RA) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rheumatoid Arthritis (RA)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rheumatoid Arthritis (RA) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Rheumatoid Arthritis (RA) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Abivax
• Kymera Therapeutics
• Akari Therapeutics
• Sierra Oncology
• Neutrolis Therapeutics
• Centivax
• Taisho
• Hope Biosciences
• UCB
• Galmed Pharmaceuticals
• Celon Pharma
• Jiangsu Hengrui Medicine Co.
• Cyxone
• Oryn Therapeutics

Key Products

• ABX464
• KT 474
• Nomacopan
• Momelotinib
• NTR 441
• Anti-CXCR5 antibody
• Ozoralizumab
• HB adMSCs
• Olokizumab
• Amilo-5MER
• CPL-409116
• SHR 0302
• Rabeximod
• ORTD 1

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/fuc8uv

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900